Outcome of interleukin 2 (IL2) targeted therapy in acute dextran sodium sulfate (DSS)-induced colitis
| DSS colitis | IL2–DT | IL2–cas | |
| Clinical score | 7.8 (1.2) | 8.4 (1.1) | 6.0 (0.7)* |
| Colon length (mm) | 66.3 (6) | 81.2 (1)† | 80 (4)† |
| Splenocytes (×106) | 142 (21) | 99 (18)† | 166 (13)* |
| Spleen CD4+ (×106) | 36 (3.4) | 29.5 (2.2)† | 46 (6)*† |
| Spleen CD25+/CD4+ (%) | 6 (1.3) | 8.3 (0.4)† | 8.3 (1.2)† |
| Spleen FoxP3+/CD4+ (%) | 6.1 (1.4) | 4.2 (0.8)† | 7.3 (1.3)* |
| Spleen CD25+FoxP3+/CD4+ (%) | 3.1 (0.4) | 3.3 (0.5) | 4.8 (0.8)*† |
Results are given as mean (SD).
Clinical score includes weight loss, stool consistency and bleeding.
*p<0.01 vs IL2–DT.
†p<0.01 vs DSS colitis.
cas, caspase-3.